ID   FHOD1_HUMAN             Reviewed;        1164 AA.
AC   Q9Y613; Q59F76; Q6Y1F2; Q76MS8; Q8N521;
DT   21-FEB-2001, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   28-JUN-2023, entry version 194.
DE   RecName: Full=FH1/FH2 domain-containing protein 1;
DE   AltName: Full=Formin homolog overexpressed in spleen 1;
DE            Short=FHOS;
DE   AltName: Full=Formin homology 2 domain-containing protein 1;
GN   Name=FHOD1; Synonyms=FHOS, FHOS1;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RX   PubMed=10352228; DOI=10.1016/s0378-1119(99)00127-4;
RA   Westendorf J.J., Mernaugh R., Hiebert S.W.;
RT   "Identification and characterization of a protein containing formin
RT   homology (FH1/FH2) domains.";
RL   Gene 232:173-182(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA], FUNCTION, AND SUBUNIT.
RX   PubMed=14576350; DOI=10.1242/jcs.00769;
RA   Takeya R., Sumimoto H.;
RT   "Fhos, a mammalian formin, directly binds to F-actin via a region N-
RT   terminal to the FH1 domain and forms a homotypic complex via the FH2 domain
RT   to promote actin fiber formation.";
RL   J. Cell Sci. 116:4567-4575(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND SUBUNIT.
RX   PubMed=15138285; DOI=10.1242/jcs.01113;
RA   Gill M.B., Roecklein-Canfield J., Sage D.R., Zambela-Soediono M.,
RA   Longtine N., Uknis M., Fingeroth J.D.;
RT   "EBV attachment stimulates FHOS/FHOD1 redistribution and co-aggregation
RT   with CD21: formin interactions with the cytoplasmic domain of human CD21.";
RL   J. Cell Sci. 117:2709-2720(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Prostate;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [5]
RP   PROTEIN SEQUENCE OF 2-19.
RC   TISSUE=Platelet;
RX   PubMed=12665801; DOI=10.1038/nbt810;
RA   Gevaert K., Goethals M., Martens L., Van Damme J., Staes A., Thomas G.R.,
RA   Vandekerckhove J.;
RT   "Exploring proteomes and analyzing protein processing by mass spectrometric
RT   identification of sorted N-terminal peptides.";
RL   Nat. Biotechnol. 21:566-569(2003).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 148-1164.
RC   TISSUE=Spleen;
RA   Totoki Y., Toyoda A., Takeda T., Sakaki Y., Tanaka A., Yokoyama S.,
RA   Ohara O., Nagase T., Kikuno R.F.;
RL   Submitted (MAR-2005) to the EMBL/GenBank/DDBJ databases.
RN   [7]
RP   FUNCTION, AUTOINHIBITION, AND SUBCELLULAR LOCATION.
RX   PubMed=15878344; DOI=10.1016/j.yexcr.2005.02.006;
RA   Gasteier J.E., Schroeder S., Muranyi W., Madrid R., Benichou S.,
RA   Fackler O.T.;
RT   "FHOD1 coordinates actin filament and microtubule alignment to mediate cell
RT   elongation.";
RL   Exp. Cell Res. 306:192-202(2005).
RN   [8]
RP   DOMAIN DAD, AND AUTOINHIBITION.
RX   PubMed=16361249; DOI=10.1074/jbc.m509226200;
RA   Schonichen A., Alexander M., Gasteier J.E., Cuesta F.E., Fackler O.T.,
RA   Geyer M.;
RT   "Biochemical characterization of the diaphanous autoregulatory interaction
RT   in the formin homology protein FHOD1.";
RL   J. Biol. Chem. 281:5084-5093(2006).
RN   [9]
RP   FUNCTION, SUBCELLULAR LOCATION, INTERACTION WITH ROCK1, AND
RP   PHOSPHORYLATION.
RX   PubMed=18694941; DOI=10.1074/jbc.m801800200;
RA   Hannemann S., Madrid R., Stastna J., Kitzing T., Gasteier J.,
RA   Schoenichen A., Bouchet J., Jimenez A., Geyer M., Grosse R., Benichou S.,
RA   Fackler O.T.;
RT   "The diaphanous-related formin FHOD1 associates with ROCK1 and promotes
RT   Src-dependent plasma membrane blebbing.";
RL   J. Biol. Chem. 283:27891-27903(2008).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-498, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18220336; DOI=10.1021/pr0705441;
RA   Cantin G.T., Yi W., Lu B., Park S.K., Xu T., Lee J.-D., Yates J.R. III;
RT   "Combining protein-based IMAC, peptide-based IMAC, and MudPIT for efficient
RT   phosphoproteomic analysis.";
RL   J. Proteome Res. 7:1346-1351(2008).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; THR-495; SER-498 AND
RP   SER-523, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Platelet;
RX   PubMed=18088087; DOI=10.1021/pr0704130;
RA   Zahedi R.P., Lewandrowski U., Wiesner J., Wortelkamp S., Moebius J.,
RA   Schuetz C., Walter U., Gambaryan S., Sickmann A.;
RT   "Phosphoproteome of resting human platelets.";
RL   J. Proteome Res. 7:526-534(2008).
RN   [12]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-367; SER-486; SER-523 AND
RP   SER-573, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [13]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-523 AND THR-690, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [14]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [15]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [16]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-486; SER-498; SER-523 AND
RP   THR-690, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-573, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
CC   -!- FUNCTION: Required for the assembly of F-actin structures, such as
CC       stress fibers. Depends on the Rho-ROCK cascade for its activity.
CC       Contributes to the coordination of microtubules with actin fibers and
CC       plays a role in cell elongation. Acts synergistically with ROCK1 to
CC       promote SRC-dependent non-apoptotic plasma membrane blebbing.
CC       {ECO:0000269|PubMed:14576350, ECO:0000269|PubMed:15878344,
CC       ECO:0000269|PubMed:18694941}.
CC   -!- SUBUNIT: Self-associates via the FH2 domain. Binds to F-actin via its
CC       N-terminus. Binds to the cytoplasmic domain of CD21 via its C-terminus.
CC       Interacts with ROCK1 in a Src-dependent manner.
CC       {ECO:0000269|PubMed:14576350, ECO:0000269|PubMed:15138285,
CC       ECO:0000269|PubMed:18694941}.
CC   -!- INTERACTION:
CC       Q9Y613; Q9Y613: FHOD1; NbExp=9; IntAct=EBI-348433, EBI-348433;
CC       Q9Y613; Q8WXH0: SYNE2; NbExp=4; IntAct=EBI-348433, EBI-2372294;
CC       Q9Y613; P19474: TRIM21; NbExp=3; IntAct=EBI-348433, EBI-81290;
CC       Q9Y613; Q6ZWQ0-1: Syne2; Xeno; NbExp=2; IntAct=EBI-348433, EBI-16108623;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Cytoplasm, cytoskeleton. Cell
CC       projection, bleb. Note=Predominantly cytoplasmic.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Highly expressed in spleen.
CC   -!- DOMAIN: The DAD domain regulates activation via by an autoinhibitory
CC       interaction with the GBD/FH3 domain. This autoinhibition is released
CC       upon competitive binding of an activated GTPase. The release of DAD
CC       allows the FH2 domain to then nucleate and elongate nonbranched actin
CC       filaments. {ECO:0000269|PubMed:16361249}.
CC   -!- PTM: Phosphorylated by ROCK1. {ECO:0000269|PubMed:18694941}.
CC   -!- SIMILARITY: Belongs to the formin homology family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AF113615; AAD39906.1; -; mRNA.
DR   EMBL; AB041046; BAD06250.1; -; mRNA.
DR   EMBL; AY192154; AAO38757.1; -; mRNA.
DR   EMBL; BC033084; AAH33084.1; -; mRNA.
DR   EMBL; AB209584; BAD92821.1; -; mRNA.
DR   CCDS; CCDS10834.1; -.
DR   RefSeq; NP_037373.2; NM_013241.2.
DR   PDB; 3DAD; X-ray; 2.30 A; A/B=1-339.
DR   PDB; 6XF1; X-ray; 2.80 A; B/D=14-334.
DR   PDB; 6XF2; X-ray; 7.11 A; B/D=14-334.
DR   PDBsum; 3DAD; -.
DR   PDBsum; 6XF1; -.
DR   PDBsum; 6XF2; -.
DR   AlphaFoldDB; Q9Y613; -.
DR   SMR; Q9Y613; -.
DR   BioGRID; 118877; 58.
DR   DIP; DIP-31134N; -.
DR   IntAct; Q9Y613; 31.
DR   MINT; Q9Y613; -.
DR   STRING; 9606.ENSP00000258201; -.
DR   GlyGen; Q9Y613; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; Q9Y613; -.
DR   MetOSite; Q9Y613; -.
DR   PhosphoSitePlus; Q9Y613; -.
DR   SwissPalm; Q9Y613; -.
DR   BioMuta; FHOD1; -.
DR   DMDM; 62512187; -.
DR   EPD; Q9Y613; -.
DR   jPOST; Q9Y613; -.
DR   MassIVE; Q9Y613; -.
DR   MaxQB; Q9Y613; -.
DR   PaxDb; Q9Y613; -.
DR   PeptideAtlas; Q9Y613; -.
DR   ProteomicsDB; 86575; -.
DR   Antibodypedia; 15694; 181 antibodies from 26 providers.
DR   DNASU; 29109; -.
DR   Ensembl; ENST00000258201.9; ENSP00000258201.4; ENSG00000135723.14.
DR   GeneID; 29109; -.
DR   KEGG; hsa:29109; -.
DR   MANE-Select; ENST00000258201.9; ENSP00000258201.4; NM_013241.3; NP_037373.2.
DR   UCSC; uc002esl.4; human.
DR   AGR; HGNC:17905; -.
DR   CTD; 29109; -.
DR   DisGeNET; 29109; -.
DR   GeneCards; FHOD1; -.
DR   HGNC; HGNC:17905; FHOD1.
DR   HPA; ENSG00000135723; Tissue enhanced (lymphoid tissue, skeletal muscle).
DR   MIM; 606881; gene.
DR   neXtProt; NX_Q9Y613; -.
DR   OpenTargets; ENSG00000135723; -.
DR   PharmGKB; PA28143; -.
DR   VEuPathDB; HostDB:ENSG00000135723; -.
DR   eggNOG; KOG1925; Eukaryota.
DR   GeneTree; ENSGT00940000160212; -.
DR   HOGENOM; CLU_000814_0_0_1; -.
DR   InParanoid; Q9Y613; -.
DR   OMA; VRVMQFC; -.
DR   OrthoDB; 2918313at2759; -.
DR   PhylomeDB; Q9Y613; -.
DR   TreeFam; TF316268; -.
DR   PathwayCommons; Q9Y613; -.
DR   SignaLink; Q9Y613; -.
DR   SIGNOR; Q9Y613; -.
DR   BioGRID-ORCS; 29109; 9 hits in 1159 CRISPR screens.
DR   ChiTaRS; FHOD1; human.
DR   EvolutionaryTrace; Q9Y613; -.
DR   GeneWiki; FHOD1; -.
DR   GenomeRNAi; 29109; -.
DR   Pharos; Q9Y613; Tbio.
DR   PRO; PR:Q9Y613; -.
DR   Proteomes; UP000005640; Chromosome 16.
DR   RNAct; Q9Y613; protein.
DR   Bgee; ENSG00000135723; Expressed in spleen and 131 other tissues.
DR   ExpressionAtlas; Q9Y613; baseline and differential.
DR   Genevisible; Q9Y613; HS.
DR   GO; GO:0032059; C:bleb; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005856; C:cytoskeleton; IBA:GO_Central.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0014704; C:intercalated disc; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:BHF-UCL.
DR   GO; GO:0051015; F:actin filament binding; IBA:GO_Central.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0019904; F:protein domain specific binding; IPI:CAFA.
DR   GO; GO:0043621; F:protein self-association; IMP:CAFA.
DR   GO; GO:0030866; P:cortical actin cytoskeleton organization; IBA:GO_Central.
DR   GO; GO:0051660; P:establishment of centrosome localization; IEA:Ensembl.
DR   GO; GO:0007097; P:nuclear migration; IEA:Ensembl.
DR   GO; GO:0051496; P:positive regulation of stress fiber assembly; IDA:BHF-UCL.
DR   GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IDA:BHF-UCL.
DR   GO; GO:0051492; P:regulation of stress fiber assembly; IMP:CAFA.
DR   DisProt; DP00448; -.
DR   Gene3D; 1.20.58.2220; Formin, FH2 domain; 1.
DR   Gene3D; 1.25.10.10; Leucine-rich Repeat Variant; 1.
DR   InterPro; IPR011989; ARM-like.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR015425; FH2_Formin.
DR   InterPro; IPR042201; FH2_Formin_sf.
DR   InterPro; IPR041387; FHOD1_GBD_N.
DR   InterPro; IPR014768; GBD/FH3_dom.
DR   PANTHER; PTHR45920:SF2; FH1/FH2 DOMAIN-CONTAINING PROTEIN 1; 1.
DR   PANTHER; PTHR45920; FORMIN HOMOLOGY 2 DOMAIN CONTAINING, ISOFORM I; 1.
DR   Pfam; PF02181; FH2; 1.
DR   Pfam; PF18382; Formin_GBD_N; 1.
DR   SMART; SM00498; FH2; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF101447; Formin homology 2 domain (FH2 domain); 1.
DR   PROSITE; PS51444; FH2; 1.
DR   PROSITE; PS51232; GBD_FH3; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Actin-binding; Cell projection; Coiled coil; Cytoplasm;
KW   Cytoskeleton; Direct protein sequencing; Phosphoprotein;
KW   Reference proteome.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|PubMed:12665801"
FT   CHAIN           2..1164
FT                   /note="FH1/FH2 domain-containing protein 1"
FT                   /id="PRO_0000194905"
FT   DOMAIN          53..458
FT                   /note="GBD/FH3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00579"
FT   DOMAIN          487..615
FT                   /note="FH1"
FT   DOMAIN          616..1013
FT                   /note="FH2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00774"
FT   DOMAIN          1053..1133
FT                   /note="DAD"
FT   REGION          340..411
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          470..500
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          566..619
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          612..807
FT                   /note="Interaction with ROCK1"
FT                   /evidence="ECO:0000269|PubMed:18694941"
FT   REGION          1020..1143
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COILED          884..921
FT                   /evidence="ECO:0000255"
FT   COMPBIAS        340..369
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        570..610
FT                   /note="Pro residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   COMPBIAS        1070..1120
FT                   /note="Polar residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOD_RES         367
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18691976"
FT   MOD_RES         486
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         495
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18088087"
FT   MOD_RES         498
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18220336, ECO:0007744|PubMed:23186163"
FT   MOD_RES         523
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18088087,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         573
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         690
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:23186163"
FT   CONFLICT        249
FT                   /note="S -> T (in Ref. 1; AAD39906 and 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264
FT                   /note="E -> D (in Ref. 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        277
FT                   /note="T -> M (in Ref. 2; BAD06250)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        307..308
FT                   /note="EA -> DT (in Ref. 1; AAD39906 and 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        359
FT                   /note="E -> D (in Ref. 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        387
FT                   /note="S -> T (in Ref. 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        533
FT                   /note="P -> L (in Ref. 6; BAD92821)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        633..634
FT                   /note="EL -> DV (in Ref. 1; AAD39906)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        689
FT                   /note="R -> Q (in Ref. 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        700
FT                   /note="S -> T (in Ref. 1; AAD39906)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        745
FT                   /note="E -> G (in Ref. 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        751
FT                   /note="E -> G (in Ref. 1; AAD39906)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        849
FT                   /note="E -> D (in Ref. 1; AAD39906)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1061
FT                   /note="P -> L (in Ref. 1; AAD39906 and 3; AAO38757)"
FT                   /evidence="ECO:0000305"
FT   STRAND          15..22
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           28..30
FT                   /evidence="ECO:0007829|PDB:6XF1"
FT   STRAND          36..39
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   STRAND          42..46
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           51..53
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           55..61
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   STRAND          68..75
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   TURN            76..78
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   STRAND          84..86
FT                   /evidence="ECO:0007829|PDB:6XF1"
FT   TURN            88..93
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           98..100
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           102..104
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   STRAND          109..114
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           116..129
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           132..147
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           152..158
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           161..169
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           174..187
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           191..199
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           201..209
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           210..212
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           216..232
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           234..236
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           237..251
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           257..263
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   TURN            264..267
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           271..287
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           291..303
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           306..314
FT                   /evidence="ECO:0007829|PDB:3DAD"
FT   HELIX           321..338
FT                   /evidence="ECO:0007829|PDB:3DAD"
SQ   SEQUENCE   1164 AA;  126551 MW;  E6C7AE1FB8DC3FC7 CRC64;
     MAGGEDRGDG EPVSVVTVRV QYLEDTDPFA CANFPEPRRA PTCSLDGALP LGAQIPAVHR
     LLGAPLKLED CALQVSPSGY YLDTELSLEE QREMLEGFYE EISKGRKPTL ILRTQLSVRV
     NAILEKLYSS SGPELRRSLF SLKQIFQEDK DLVPEFVHSE GLSCLIRVGA AADHNYQSYI
     LRALGQLMLF VDGMLGVVAH SDTIQWLYTL CASLSRLVVK TALKLLLVFV EYSENNAPLF
     IRAVNSVAST TGAPPWANLV SILEEKNGAD PELLVYTVTL INKTLAALPD QDSFYDVTDA
     LEQQGMEALV QRHLGTAGTD VDLRTQLVLY ENALKLEDGD IEEAPGAGGR RERRKPSSEE
     GKRSRRSLEG GGCPARAPEP GPTGPASPVG PTSSTGPALL TGPASSPVGP PSGLQASVNL
     FPTISVAPSA DTSSERSIYK ARFLENVAAA ETEKQVALAQ GRAETLAGAM PNEAGGHPDA
     RQLWDSPETA PAARTPQSPA PCVLLRAQRS LAPEPKEPLI PASPKAEPIW ELPTRAPRLS
     IGDLDFSDLG EDEDQDMLNV ESVEAGKDIP APSPPLPLLS GVPPPPPLPP PPPIKGPFPP
     PPPLPLAAPL PHSVPDSSAL PTKRKTVKLF WRELKLAGGH GVSASRFGPC ATLWASLDPV
     SVDTARLEHL FESRAKEVLP SKKAGEGRRT MTTVLDPKRS NAINIGLTTL PPVHVIKAAL
     LNFDEFAVSK DGIEKLLTMM PTEEERQKIE EAQLANPDIP LGPAENFLMT LASIGGLAAR
     LQLWAFKLDY DSMEREIAEP LFDLKVGMEQ LVQNATFRCI LATLLAVGNF LNGSQSSGFE
     LSYLEKVSEV KDTVRRQSLL HHLCSLVLQT RPESSDLYSE IPALTRCAKV DFEQLTENLG
     QLERRSRAAE ESLRSLAKHE LAPALRARLT HFLDQCARRV AMLRIVHRRV CNRFHAFLLY
     LGYTPQAARE VRIMQFCHTL REFALEYRTC RERVLQQQQK QATYRERNKT RGRMITETEK
     FSGVAGEAPS NPSVPVAVSS GPGRGDADSH ASMKSLLTSR PEDTTHNRRS RGMVQSSSPI
     MPTVGPSTAS PEEPPGSSLP SDTSDEIMDL LVQSVTKSSP RALAARERKR SRGNRKSLRR
     TLKSGLGDDL VQALGLSKGP GLEV
//
